Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Tapashi Dalvi"'
Autor:
Tapashi Dalvi, Mette Nørgaard, Jon P. Fryzek, Naimisha Movva, Lars Pedersen, Hanh Pham Hansen, Jill Walker, Anita Midha, Norah Shire, Anne-Marie Boothman, James Rigas, Anders Mellemgaard, Torben R. Rasmussen, Stephen Hamilton-Dutoit, Deirdre Cronin-Fenton
Publikováno v:
PLoS ONE, Vol 18, Iss 4 (2023)
Introduction Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki
Externí odkaz:
https://doaj.org/article/96a68e6586004ab396c586bf8e142765
Autor:
Deirdre Cronin-Fenton, Tapashi Dalvi, Naimisha Movva, Lars Pedersen, Hanh Hansen, Jon Fryzek, Elizabeth Hedgeman, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, Stephen Hamilton-Dutoit, Mette Nørgaard
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage
Externí odkaz:
https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07
Autor:
Joyce O’Shaughnessy, Christine Brezden-Masley, Marina Cazzaniga, Tapashi Dalvi, Graham Walker, James Bennett, Shozo Ohsumi
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Methods Elig
Externí odkaz:
https://doaj.org/article/523e73d0d251406193a399f0c8dd0628
Autor:
Shozo Ohsumi, Chuan Hsun Chang, Graham Walker, Kyung Hae Jung, Ming Shen Dai, Joyce A. O'Shaughnessy, Judith Balmaña, Masato Takahashi, Eisuke Fukuma, Su Jin Koh, Tapashi Dalvi, Takanori Ishida, James Bennett
Publikováno v:
Breast Cancer (Tokyo, Japan)
Scientia
Scientia
Background The multinational BREAKOUT study (NCT03078036) sought to determine the prevalence of germline BRCA1/2 (gBRCA1/2) and somatic BRCA1/2 (sBRCA1/2) mutations and mutations in other homologous recombination repair (HRR) genes in women with HER2
Autor:
Elizabeth Hedgeman, Jon P. Fryzek, Lars Pedersen, Deirdre Cronin-Fenton, Mette Nørgaard, Torben Riis Rasmussen, Naimisha Movva, Tapashi Dalvi, Stephen Hamilton-Dutoit, Hanh Hansen, Anders Mellemgaard, Norah J. Shire
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, 16892 . https://doi.org/10.1038/s41598-021-96486-2
Cronin-Fenton, D, Dalvi, T, Movva, N, Pedersen, L, Hansen, H, Fryzek, J, Hedgeman, E, Mellemgaard, A, Rasmussen, T R, Shire, N, Hamilton-Dutoit, S & Nørgaard, M 2021, ' PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients : a Danish cohort study ', Scientific Reports, vol. 11, no. 1, pp. 16892 . https://doi.org/10.1038/s41598-021-96486-2
Scientific Reports
Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unres
Autor:
Jerzy E. Tyczynski, Lia Gutierrez, Rishi Deka, Amy Sainski, Junjie Ma, Tapashi Dalvi, David D. Stenehjem, Casey R. Tak, Marisa B. Schauerhamer, Claire Telford, Joseph Biskupiak, James A. Kaye, Sudhir Unni, Diana I. Brixner, Hillevi Bauer, Xiangyang Ye
Publikováno v:
Breast Cancer Research and Treatment. 186:839-850
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Autor:
Mette Nørgaard, Torben Riis Rasmussen, Norah J. Shire, Hanh Hansen, Anders Mellemgaard, Anita Midha, Jill Walker, Elizabeth Hedgeman, Lars Pedersen, Tapashi Dalvi, Deirdre Cronin-Fenton, Stephen Hamilton-Dutoit, J. Rigas, Anne-Marie Boothman, Jon P. Fryzek
Publikováno v:
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A-M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, pp. 101976 . https://doi.org/10.1016/j.canep.2021.101976
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, 101976 . https://doi.org/10.1016/j.canep.2021.101976
Hedgeman, E, Nørgaard, M, Dalvi, T, Pedersen, L, Hansen, H P, Walker, J, Midha, A, Shire, N, Boothman, A M, Fryzek, J P, Rigas, J, Mellemgaard, A, Rasmussen, T R, Hamilton-Dutoit, S & Cronin-Fenton, D 2021, ' Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark ', Cancer epidemiology, vol. 73, 101976 . https://doi.org/10.1016/j.canep.2021.101976
BACKGROUND: PD-L1 expression on tumor cells (TCs) or immune cells (ICs) may be used as a prognostic marker for survival in patients with NSCLC. We characterized PD-L1 expression on TCs or ICs in a patient cohort with NSCLC to determine associations b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46578e6da5a61a4e3e492aa29027f4dc
https://pure.au.dk/portal/da/publications/programmed-cell-death-ligand1-expression-and-survival-in-a-cohort-of-patients-with-nonsmall-cell-lung-cancer-receiving-firstline-through-thirdline-therapy-in-denmark(d9615987-9773-43dc-9b60-de7ac1e0059e).html
https://pure.au.dk/portal/da/publications/programmed-cell-death-ligand1-expression-and-survival-in-a-cohort-of-patients-with-nonsmall-cell-lung-cancer-receiving-firstline-through-thirdline-therapy-in-denmark(d9615987-9773-43dc-9b60-de7ac1e0059e).html
Autor:
Tapashi Dalvi, Susan McCutcheon, Kimmie K. McLaurin, Jenna Collins, James Bennett, Beth L. Nordstrom, Brian R. Murphy, Josefa Maria Briceno, Robert Hettle
Publikováno v:
Cancer Research. 79:P1-09
Background: Limited data exist on the natural history (treated with standard of care) of metastatic breast cancer (mBC) characterized by germline breast cancer susceptibility gene mutations (gBRCAm). Real-world data examining survival for patients wi
Autor:
S Maclachlan, Kimmie K. McLaurin, Josefa Maria Briceno, Robert Hettle, James Bennett, I Herr, Susan McCutcheon, Tapashi Dalvi
Publikováno v:
Cancer Research. 79:P1-09
Objective: To describe the demographics, clinical/disease characteristics and treatment patterns of patients with germline BRCA mutated (gBRCAm) metastatic breast cancer (mBC) as compared to those with gBRCA wild type (wt) and those who are untested